## EW: Edwards Lifesciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.4% below STRENGTH zone (3.0-6.0%); PEG 4.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($83.60)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 3, Bearish: 1)

**1. How Do Investors Really Feel About Edwards Lifesciences Corp?**
- Source: Sahm | 20251225T030827 | Somewhat-Bearish | Relevance: 100%
- Edwards Lifesciences Corp's short interest as a percent of float has risen by 7.26% since its last report, indicating increased bearish sentiment amongst investors. However, the company's short interest is lower than the average of its peers. The article highlights that an increase in short interest can signal more bearish sentiment for a stock, but also notes that it doesn't necessarily mean the stock will fall in the near-term.

**2. FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy**
- Source: BioSpace | 20251225T010843 | Bullish | Relevance: 100%
- The FDA has approved Edwards Lifesciences' SAPIEN M3 mitral valve replacement system, marking the first transseptal transcatheter therapy for mitral regurgitation (MR). This system is intended for symptomatic patients unsuitable for surgery or other repair therapies. Clinical trials showed significant MR elimination and improved patient quality of life.

**3. HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS**
- Source: Finviz | 20251224T124500 | Bearish | Relevance: 100%
- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders of Edwards stock to contact them to discuss potential legal rights and options, including corporate governance reforms or the return of funds to the company. Halper Sadeh LLC handles these actions on a contingent fee basis, emphasizing that shareholder participation can lead to improved company policies and enhanced shareholder value.

**4. Edwards Lifesciences Corporation $EW Shares Sold by OLD National Bancorp IN**
- Source: MarketBeat | 20251224T110801 | Somewhat-Bullish | Relevance: 100%
- OLD National Bancorp IN significantly reduced its stake in Edwards Lifesciences (NYSE:EW) by 69.4% in Q3, selling 132,226 shares and retaining 58,421 shares valued at $4.543 million. Despite this, Wall Street analysts maintain a "Moderate Buy" consensus for EW, with an average price target of $93.95, following multiple rating upgrades. Institutional investors collectively hold about 79.46% of the company's stock, though some insiders have recently decreased their holdings.

**5. FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy**
- Source: Yahoo Finance | 20251224T040844 | Bullish | Relevance: 100%
- Edwards Lifesciences has received FDA approval for its SAPIEN M3 mitral valve replacement system, marking it as the first transseptal transcatheter therapy for mitral regurgitation (MR). This system is indicated for patients with symptomatic moderate-to-severe or severe MR who are unsuitable for traditional surgery or TEER therapy. The SAPIEN M3 system provides a fully percutaneous mitral valve replacement, demonstrating significant MR elimination and improved patient quality of life in clinical trials.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 11, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $100 | $90 | +11% |
| 2025-12-17 | Canaccord Genui | $87 | $89 | -2% |
| 2025-12-16 | Baird | $87 | $88 | -1% |
| 2025-12-11 | Citigroup | $101 | $96 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | up | Overweight |
| 2025-12-17 | Canaccord Genui | main | Hold |
| 2025-12-16 | Baird | main | Neutral |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 12 ($3.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. Valuation stretched: PEG 4.9x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 11 raises (avg +5%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.86 signals overvaluation risk, limited margin of safety. Forward P/E 30.2x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $51.0B |
| Beta | 0.97 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.86 |
| Forward P/E | 30.2 |
| Current P/E | 33.6 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.5% to 0.4% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.6pp (needs >3.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.36% (CS: 82) | Neutral |
| RSI_14 | 60.4 | Neutral |
| MACD Histogram | 0.11 | Bullish |
| vs SMA20 | 1.021x | Above |
| vs SMA50 | 1.042x | Above |
| vs SMA200 | 1.118x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $86.84
- **Stop Loss:** $83.60 (3.7% risk)
- **Target:** $90.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 407
- **Position Value:** $35,343.88
- **Portfolio %:** 35.34%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*